Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track DVA with free AI briefings, catalyst countdowns, and dilution alerts.

DVA · DAVITA INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$727.2M Cash on Hand

CF+ Cash Runway

Follow DVA by email Get an email when DVA pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about DVA, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

Apr 2021 · N/A · Results Expected · COVID-19 Progression in End-Stage Kidney Disease
Registry primary completion date, not a results date
Feb 2021 · N/A · Results Expected · Registry of Sustained Immunity to COVID-19 Among ESKD Patients
Registry primary completion date, not a results date
Oct 2018 · Phase 3 · Results Expected · Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to
Registry primary completion date, not a results date
Oct 2017 · N/A · Results Expected · CSD170301: An Unblinded, Parallel, Randomized Study to Assess Nicotine Uptake in Smokers F
Registry primary completion date, not a results date
Sep 2017 · N/A · Results Expected · CSD170303: Study to Assess Nicotine Uptake in Smokers From Electronic Cigarettes
Registry primary completion date, not a results date
Sep 2017 · N/A · Results Expected · CSD170302: Study to Assess Nicotine Uptake in Smokers From Electronic Cigarettes
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
Heparin	Kidney Failure, Chronic	Phase 3 · NCT02651428	Completed
Neutrolin	Kidney Failure, Chronic	Phase 3 · NCT02651428	Completed
Pentoxifylline	Hypoalbuminemia	Phase 3 · NCT00561093	Completed
FMX-8	Anemia of Chronic Disease	Phase 2 · NCT01873534	Terminated
Thymalfasin	COVID-19	Phase 2 · NCT04428008	Completed
Cavosonstat	Drug Interaction Potentiation	Phase 1 · NCT02500667	Completed
Nalbuphine	Uremic Pruritus	Phase 1 · NCT02373215	Completed

Also used in these trials (approved or third-party drugs, not DVA's own candidates): Calcium Acetate, Lanthanum Carbonate, Sevelamer Carbonate, Elbasvir And Grazoprevir, Rifampin.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

DVA holds $727.2M in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

No operating cash burn in latest filings

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when DVA files for a raise →

Get the full DVA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for DVA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z